Lundbeck's biggest ever clinical trial starts in North America  

Lundbeck and Cephalon commence clinical trial of Parkinson's Disease drug

H. Lundbeck A/S and US biopharma company Cephalon, Inc. have announced the start of a large North American Phase 2/3 clinical trial of a new drug treatment for delaying the progression of Parkinson's disease. The study expects to enrol approximately 800 patients at up to 65 locations in the US and Canada. Three years ago, Lundbeck invested USD 40 million in Cephalon to gain a share of the development and sales rights to the drug, codenamed CEP-1347. Lundbeck holds exclusive commercial rights to the compound in Europe and certain other territories. If clinical studies go well, CEP-1347 could reach the market by 2007/8.


H. Lundbeck A/S develops and markets drugs for the treatment of psychiatric and neurological disorders. In 2001, the company's revenue was DKK 7.7 billion (USD 1 billion) and the number of employees was 4,000. Cephalon develops and markets innovative products to treat sleep and neurological disorders, cancer and pain. The company currently employs 1,200 people in the United States and Europe.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×